StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM)

Investment analysts at StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a research note issued to investors on Sunday. The firm set a “sell” rating on the stock.

CEL-SCI Price Performance

Shares of CVM stock opened at $0.21 on Friday. The business’s fifty day moving average is $0.33 and its 200 day moving average is $0.58. The company has a quick ratio of 1.09, a current ratio of 1.07 and a debt-to-equity ratio of 0.66. The stock has a market cap of $16.71 million, a price-to-earnings ratio of -0.43 and a beta of 0.95. CEL-SCI has a twelve month low of $0.18 and a twelve month high of $2.39.

Institutional Trading of CEL-SCI

An institutional investor recently raised its position in CEL-SCI stock. Thoroughbred Financial Services LLC grew its position in shares of CEL-SCI Co. (NYSE:CVM) by 40.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 191,661 shares of the company’s stock after buying an additional 54,900 shares during the quarter. Thoroughbred Financial Services LLC owned 0.26% of CEL-SCI worth $76,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.